BCHE and Lewy body dementia: Confirmation of DLB would lead to reconsidering treatment options, possibly moving away from AD-specific treatments like monoclonal antibodies and towards DLB-targeted therapies such as cholinesterase inhibitors to improve cognitive and psychiatric symptoms.